Formulation and interpretation of the Chinese Guidelines for Surgical Treatment of Obesity and Type 2 Diabetes Mellitus

Du, Yanmin; Zhang, Jianlu; Chen, Guanyang; Sun, Zhipeng

doi:10.5582/bst.2021.01287

Cited by 11 publications

(12 citation statements)

References 26 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the result of the risk analysis, tumor was the major factor driving the occurrence of death instead of the nontumor factor, which means metabolic complications, like cardiovascular disease, diabetic nephropathy, or apoplexy. It strengthened reliability of the conclusion and clarified that the negative impact of MetS mainly focus on the tumor and liver for patients with HCC rather than other organs or systems ( 29 ).…”

Section: Discussionmentioning

confidence: 79%

The Effect of Metabolic Syndrome on the Outcome of Hepatitis B-Associated Hepatocellular Carcinoma Patients After Hepatectomy: A Multicenter Study

et al. 2022

View full text Add to dashboard Cite

Background and AimsWith changes in dietary patterns and modern lifestyles, the prevalence of metabolic syndrome (MetS) in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) patients is increasing. The purpose of our study is to explore the impact of MetS on the prognosis of HBV-associated HCC patients following radical hepatectomy.MethodsData on consecutive HCC patients who underwent radical hepatectomy were prospectively obtained and retrospectively analyzed from seven medical centers in west areas of China. Propensity score matching (PSM) analysis was conducted to balance the heterogeneity between MetS-HBV-HCC group and HBV-HCC group. Surgical outcomes have been contrasted between the two groups.ResultsIn 984 patients, 179 (18.19%) were diagnosed with MetS. Patients in the MetS-HBV-HCC group had higher CCI score (8.7 [0.0, 12.2] vs. 0.0 [0.0, 8.7], p = 0.048) and a higher rate of severe complications (Clavien–Dindo ≥3, 7.82% vs. 4.10%, p = 0.035), to be more precise: postoperative liver failure, hydrothorax, and hyperglycemia. Patients in the MetS-HBV-HCC group tended to have worse 5-year overall survival (OS) rate (61.45% vs. 69.94%, p = 0.027) and recurrence-free survival (RFS) rate (62.57% vs. 53.66%, p = 0.030), consistent with the results of the competing risk models. Last, MetS was identified to be an independent unfavorable prognostic factor in the multivariate analysis.ConclusionThe involvement of MetS increased the risk of postoperative complications and worsens the overall survival and recurrence-free survival time, reminding us to be more prudent to face metabolic disorder among tumor patients.

show abstract

Section: Discussionmentioning

confidence: 79%

The Effect of Metabolic Syndrome on the Outcome of Hepatitis B-Associated Hepatocellular Carcinoma Patients After Hepatectomy: A Multicenter Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ninety reproductive-age women (18-40 years of age) meeting the following criteria were prospectively recruited for this study: 1) BMI ≥ 27.5 kg/m 2 ; 2) waist circumference ≥ 85 cm; 3) diagnosed with PCOS. All the subjects were eligible for the indication of bariatric surgery according to the guideline of the Chinese Society of Metabolic and Bariatric Surgery ( 27 ). According to the 2011 Chinese criteria based on the principles of the Rotterdam criteria, the presence of oligo-ovulation or anovulation is essential for diagnosis.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome

Xia

Ying

et al. 2022

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Objective To determine the difference in efficacy between drug and bariatric surgery therapy for women with obesity and polycystic ovary syndrome (PCOS). Design Prospective non-randomized trial. Methods A total of 90 women aged 18–40 years with body mass index (BMI) ≥ 27.5 kg/m 2 and waist circumference ≥85 cm fulfilling the 2011 Chinese diagnostic criteria for PCOS were enrolled and 81 subjects completed this study. In the drug group, patients were administered metformin and an oral contraceptive containing ethinyl-estradiol and cyproterone acetate for the first 6 months, and metformin alone for the second 6 months. In the surgical group, patients underwent laparoscopic sleeve gastrectomies. The follow-up time was 12 months. The main outcome was set as the complete remission of PCOS requiring six consecutive regular menstruation or spontaneous pregnancy. Results Median BMI at endpoint was 30.1 kg/m 2 in the drug group and 23.7 kg/m 2 in the surgical group, complete remission rate was 15% and 78%, respectively. Except endpoint BMI, no difference was observed in free androgen index, ovarian morphology, homeostasis model assessment for insulin resistance, and total weight loss between remission and non-remission patients. Logistic regression analyses also revealed that the final BMI was the major factor influencing the remission of PCOS. The cut-off points of the final BMI were 27.5 kg/m 2 for the drug group and 26 kg/m 2 for the surgical group. Overall, nearly 95% of patients with an endpoint BMI below the cut-off values achieved complete remission. Conclusion Complete remission of PCOS in patients with obesity depends on the final BMI after weight loss. Thus, bariatric surgery should be prioritized for these patients.

show abstract

“…In this retrospective study, we recruited a total of 19 men and 30 women with obesity at Shanghai Jiao Tong University Affiliated Sixth People’s Hospital between March 2015 and July 2020. The inclusion criteria were as follows: (1) men aged < 50 years and women aged < 45 years with regular menstrual cycles, and (2) fulfillment of the Chinese SG guideline criteria ( 25 ). The exclusion criteria were as follows: (1) usage of medications affecting bone metabolism, including bisphosphonates, teriparatide, and oral glucocorticoids; (2) bone diseases of different etiologies (primary hyperparathyroidism, Paget disease); (3) usage of sex steroid products; (4) missing data on age, sex, body mass index (BMI), BMD, or laboratory investigations; and (5) clinical or laboratory evidence of hepatic or renal disease, gestation or lactation, or malignant disease.…”

Section: Methodsmentioning

confidence: 99%

“…(1) men aged < 50 years and women aged < 45 years with regular menstrual cycles, and (2) fulfillment of the Chinese SG guideline criteria (25). The exclusion criteria were as follows:…”

Section: Study Design and Participantsmentioning

confidence: 99%

Sex-specific differences in bone mineral density loss after sleeve gastrectomy

Yang

Ye²,

Tu³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundSleeve gastrectomy is an effective bariatric procedure; however, sleeve gastrectomy-related adverse skeletal outcomes have been increasingly reported. High levels of sex hormone-binding globulin (SHBG) have been documented to be a risk factor of bone mineral density (BMD) loss with different effects observed between sexes. The aim of this study was to identify sex-specific changes in BMD following sleeve gastrectomy and to evaluate the role of SHBG in this process.MethodsThis retrospective study included 19 middle-aged men and 30 non-menopausal women with obesity who underwent sleeve gastrectomy in China. Anthropometrics, bone turnover markers, calciotropic hormones, BMD, SHBG, and gonadal steroids were measured preoperatively and at 6 and 12 months postoperatively. Longitudinal changes in BMD, bone turnover markers and SHBG were compared between sexes by linear mixed models. Multiple stepwise regression analysis was used to identify the predictors of BMD loss at the investigated bone sites.ResultsOver the 12-month study period, total hip and femoral neck BMD decreased, while lumbar spine BMD remained largely unchanged in both sexes. Linear mixed models revealed significant sex × time interaction effects in total hip BMD and SHBG, showing that men had a significantly greater reduction in total hip BMD and less increase in SHBG after sleeve gastrectomy than women. In the multivariate model, SHBG was significantly associated with total hip BMD loss in men (adjusted β = −0.533, P = 0.019) but not women while total estrogen was significantly associated with total hip BMD loss in women (adjusted β = 0.508, P = 0.01) but not men.ConclusionSignificant sex-specific BMD changes were observed after sleeve gastrectomy in the current study. Sleeve gastrectomy-related increase in SHBG may be a specific risk factor for total hip BMD loss in men. Our results indicate that sex-specific screening may be warranted to facilitate personalized postoperative bone care in this population.

show abstract

Formulation and interpretation of the Chinese Guidelines for Surgical Treatment of Obesity and Type 2 Diabetes Mellitus

Cited by 11 publications

References 26 publications

The Effect of Metabolic Syndrome on the Outcome of Hepatitis B-Associated Hepatocellular Carcinoma Patients After Hepatectomy: A Multicenter Study

The Effect of Metabolic Syndrome on the Outcome of Hepatitis B-Associated Hepatocellular Carcinoma Patients After Hepatectomy: A Multicenter Study

Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome

Sex-specific differences in bone mineral density loss after sleeve gastrectomy

Contact Info

Product

Resources

About